Cargando…
SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance
BACKGROUND: Methyltransferase SETDB1 is highly expressed in breast cancer (BC), however, the mechanisms by which SETDB1 promotes BC progression to endocrine therapy resistance remains elusive. In this study, we examined the mechanisms by which SETDB1 contribute to BC endocrine therapy resistance. ME...
Autores principales: | Liu, Zexuan, Liu, Junhao, Ebrahimi, Behnam, Pratap, Uday P., He, Yi, Altwegg, Kristin A., Tang, Weiwei, Li, Xiaonan, Lai, Zhao, Chen, Yidong, Shen, Liangfang, Sareddy, Gangadhara R., Viswanadhapalli, Suryavathi, Tekmal, Rajeshwar R., Rao, Manjeet K., Vadlamudi, Ratna K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991965/ https://www.ncbi.nlm.nih.gov/pubmed/35395812 http://dx.doi.org/10.1186/s13058-022-01520-4 |
Ejemplares similares
-
Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34
por: Altwegg, Kristin A., et al.
Publicado: (2023) -
Global Genomic and Proteomic Analysis Identified Critical Pathways Modulated by Proto-Oncogene PELP1 in TNBC
por: Liu, Zexuan, et al.
Publicado: (2022) -
Interaction of transcription factor AP‐2 gamma with proto‐oncogene PELP1 promotes tumorigenesis by enhancing RET signaling
por: Liu, Junhao, et al.
Publicado: (2021) -
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma
por: Pratap, Uday P, et al.
Publicado: (2021) -
PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling
por: Sareddy, Gangadhara R, et al.
Publicado: (2019)